معرفی
Dr. Paul Afolabi is a Senior Research Fellow at the University of Southampton’s Southampton Biomedical Research Centre (SBRC), funded by the National Institute for Health Research (NIHR). He holds a PhD in Biological Chemistry from the University of Southampton and specializes in developing non-invasive breath tests for metabolic dysfunction in diseases such as pancreatic cancer, liver disorders, and post-acute COVID-19. His work focuses on translating clinical research into practical diagnostic tools, including breathomics applications for early disease detection.
Key research areas include pancreatic exocrine insufficiency biomarkers, NAFLD progression, and mitochondrial function assessment. He leads initiatives like the DEPEND study, evaluating 13C breath tests for pancreatic cancer screening, and collaborates on projects analyzing post-acute COVID-19 metabolic impacts. His expertise bridges clinical and metabolic research, supporting grant applications for UK-based teams.
Dr. Afolabi’s publications span oncology, liver disease, and critical care, emphasizing interdisciplinary approaches to metabolic diagnostics. He collaborates with institutions like University Hospital Southampton and actively contributes to clinical guidelines for breath testing protocols.
